CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Homo sapiens (Human) Sandwich CLIA

FSTL2; IGFBP-7v; MAC25; PSF; TAF; IGFBP-rP1; MAC25 protein; Prostacyclin-stimulating factor; PGI2-stimulating factor; Tumor-derived adhesion factor

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Packages (Simulation)
  • CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Packages (Simulation)
  • CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Results demonstration
  • SCB673Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and the recovery rates were calculated by comparing the measured value to the expected amount of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-94 88
EDTA plasma(n=5) 86-93 90
heparin plasma(n=5) 78-90 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 95-102% 87-101% 93-101% 94-105%
EDTA plasma(n=5) 84-101% 82-99% 83-101% 80-89%
heparin plasma(n=5) 89-104% 84-98% 82-96% 96-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Insulin Like Growth Factor Binding Protein 7 (IGFBP7). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Insulin Like Growth Factor Binding Protein 7 (IGFBP7). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Insulin Like Growth Factor Binding Protein 7 (IGFBP7) level in the sample or standard.;

Citations

  • Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial CellsPubmed:26974954
  • Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells.pubmed:26974954
  • Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental MethodsPubmed:30040720
  • IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung CancerPubmed: 30609749
  • Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart diseasePubmed: 30769262
  • Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophreniaPubmed: 32191705
  • Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progressionPubmed: 32286426
  • SNORD116 and growth hormone therapy impact IGFBP7 in Prader¨CWilli syndrome34040195
  • Biomarkers of persistent renal vulnerability after acute kidney injury recovery34707157
  • IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart DiseasePubmed:35204773
  • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot StudyPubmed:35625639

Recommend products